Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity
Clinical and Translational Oncology · 2023
DOI: 10.1007/s12094-023-03217-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Oncology, 2023. Verfasst von Eduardo Zatarain-Nicolás und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Hospital General Universitario Gregorio Marañón, CIBER-CV (Instituto de Salud Carlos III), Universidad Complutense, Madrid, Sp…. Hauptthemen laut MEDLINE: Myocarditis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICI) have changed the prognosis of many tumors. However, concerning associated cardiotoxicity has been reported. Little is known about the real-life incidence-specific surveillance protocols or the translational correlation between the underlying mechanisms and the clinical presentation of ICI-induced cardiotoxicity. The lack of data from prospective studies led us to review the current knowledge and to present the creation of the Spanish Immunotherapy Registry of Cardiovascular Toxicity (SIR-CVT), a prospective registry of patients receiving ICI that aims to examine the role of hsa-miR-Chr8:96, (a specific serum biomarker of myocarditis) in the early diagnosis of ICI-induced myocarditis. An exhaustive prospective cardiac imaging study will be performed before and during the first 12 months of treatment. The correlation between clinical, imaging, and immunologic parameters may improve our understanding of ICI-induced cardiotoxicity and enable simpler surveillance protocols. We assess ICI-induced cardiovascular toxicity and describe the rationale of the SIR-CVT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiology Department, Hospital General Universitario Gregorio Marañón, CIBER-CV (Instituto de Salud Carlos III), Universidad Complutense, Madrid, Spain. eduzatanico@gmail.com.
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), CIBER-CV (Instituto de Salud Carlos III), Madrid, Spain.
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Medical Oncology Department, Hospital Universitario Virgen de la Macarena, Seville, Spain.
- Cardiology Department, Complejo Asistencial Universitario de Salamanca, IBSAL, USAL, CIBER-CV (Instituto de Salud Carlos III), Salamanca, Spain.
- Cardiology Department, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBER-CV (Instituto de Salud Carlos III), Madrid, Spain.
Förderung
- Ministerio de Ciencia e Innovación
- Instituto de Salud Carlos III
Zitieren
APA
Zatarain-Nicolás, E., Martín, P., Márquez Rodas, I., Virizuela, J., Martín García, A., Mitroi, C., Cosín Sales, J., Barrios, V., Sánchez-Cabo, F., Ibañez, B., de Castro Carpeño, J., & López Fernández, T. (2023). Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-023-03217-2
Vancouver
Zatarain-Nicolás E, Martín P, Márquez Rodas I, Virizuela J, Martín García A, Mitroi C, et al. Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity. Clinical and Translational Oncology. 2023. doi:10.1007/s12094-023-03217-2
BibTeX
@article{ZatarainNicols2023,
author = {Zatarain-Nicolás, Eduardo and Martín, Pilar and Márquez Rodas, Iván and Virizuela, Juan and Martín García, Ana and Mitroi, Cristina and Cosín Sales, Juan and Barrios, Vivencio and Sánchez-Cabo, Fátima and Ibañez, Borja and de Castro Carpeño, Javier and López Fernández, Teresa},
title = {Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity},
journal = {Clinical and Translational Oncology},
year = {2023},
doi = {10.1007/s12094-023-03217-2}
}
EUVIMED